All GLG News Analyses Filed Under: Healthcare Services

The combination of a slowing economy and turbulent debt markets has finally hit the US commercial office market. Although a great deal of equity capital remains ready to invest, between the meltdown and risk-adjustment in the financing markets, deteriorating operating fundamentals and herd mentality...

I'd go with the second analyst in the article, who points out the exosting product overlap between the two companies.

Difficulty in turning the potential opportunity into sales     

This article serves as a reminder that it is institutional, not individual diversion of controlled substances that is the principal basis of this important public health concern.

The Genetic Information Nondiscrimination Act (GINA), which will soon become law, will protect Americans who choose to have genetic testing against the fear of discrimination by employers and health insurers. The idea of personalized medicine can not become a reality with out the passage of GINA.

George Barrett, the new CEO of Cardinal Health’s (CAH) Healthcare Supply Chain Services division, was refreshingly blunt in describing the need to “turnaround” the drug distribution business on last Thursday’s earning conference call.  He described the company’s market share challenges with independent...

McKesson (MCK) announced a settlement with the DEA that temporarily suspends distribution of two controlled substances from two of its distribution centers. I presume that McKesson has learned some lessons from Cardinal Health’s (CAH) troubles so the marketplace impact should be less severe.  

There are many reasons why the commercialization of human genome "information" will be ABSOLUTE CHAOS AND COST.  The three most prominent are the following:   1. Physician education is almost devoid of practical genomic teachings except for Diabetes and lipid disorders.   2. ...

The passage of this bill by the Senate and the likely passage by the house are both good for consumers as well as the companies that conduct genetic testing.

The movement to make the pharmacy supply chain safer just took a huge step forward with Friday’s introduction of H.R. 5839 Safeguarding America’s Pharmaceuticals Act of 2008. The bill is co-sponsored by Representatives Steve Buyer (R-IN), Gene Green (D-TX), Jim Matheson (D-UT), and Mike Rogers (R-MI)....